

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : Jackowski et al.

INVENTION : Biopolymer Marker Indicative Of
Disease State Having A Molecular
Weight Of 1793 Daltons

SERIAL NUMBER : 09/845,739

FILING DATE : April 30, 2001

EXAMINER : Cook, Lisa V.

GROUP ART UNIT : 1641

OUR FILE NO. : 2132.044

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450 on 9-30-2003

Mail Stop: Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION UNDER 37 CFR § 1.132

I, Ferris H. Lander, do hereby declare as follows:

1. I am a registered Patent Agent and am authorized to represent the inventor's and assignee in the application entitled "Biopolymer Marker Indicative of Disease State Having A Molecular Weight of 1793 Daltons", having U.S. Application Serial No. 09/845,739, filed April 30, 2001.

2. In the Office Action mailed on April 7, 2003, claims 3-9, 18-28 and 33-35 (as originally presented) were rejected under 35 U.S.C. 112, first paragraph because the claimed invention allegedly

contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The claims as amended have been limited to a specific biopolymer marker peptide consisting of SEQ ID NO:1 (the 1793 dalton marker) useful in methods and kits for diagnosing congestive heart failure. The method of the invention as recited in claim 36 involves a comparison of the mass spectrum profile of a peptide consisting of SEQ ID NO:1 to mass spectrum profiles of peptides elucidated from a patient sample, wherein recognition of a mass spectrum profile in the patient sample displaying the characteristic profile of the mass spectrum of the peptide consisting of SEQ ID NO:1 indicates that the patient from which the sample was obtained is suffering from congestive heart failure .

3. In order to provide data which would further support the comparison step involved in the claimed method, I contacted Dr. George Jackowski, Chief Executive Officer and Chief Science Officer of Syn-x Pharma Inc., and asked to be provided with evidence of the absence of the 1793 dalton marker in normal human sera (obtained from healthy patients).

4. This declaration (including the attached figure) is provided in order to show a comparison of the serum profile of individuals having congestive heart failure to the serum profile of non-diseased individuals, so as to evidence that the marker (the 1793 dalton peptide) was not present in normal human sera.

The attached figure, obtained from Dr. Jackowski, provides side-by-side profiles (obtained using techniques of mass spectrometry) of normal human sera versus sera from patients having congestive heart failure. This profile comparison clearly evidences the absence of the 1793 dalton marker in normal human sera. This figure does not represent results obtained from additional experimentation. The profiles were reproduced from data obtained in the original experiments performed at the time of the invention.

The undersigned declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the Application or any patent issuing thereon.

9/29/2003

Date

Ferris H. Lander

Ferris H. Lander
Reg. No. 43,377

\\Ns2\DRV_E\STAFF DATA FILES\Ferris Lander's Files\FL\AMENDMNT.PAT\2132_044.132.wpd

